Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the efficacy and safety of a FDC of imipenem/cilastatin (IMI) and relebactam (REL) [IMI/REL, MK-7655A] compared to piperacillin/tazobactam (PIP/TAZ) in the treatment of adults diagnosed with Hospital-Acquired Bacterial Pneumonia (HABP) or Ventilator-Associated Bacterial Pneumonia (VABP). The primary hypothesis is that IMI/REL is non-inferior to PIP/TAZ as measured by the incidence rate of all-cause mortality through Day 28 post-randomization.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03583333
Study type Interventional
Source Merck Sharp & Dohme LLC
Contact
Status Completed
Phase Phase 3
Start date September 18, 2018
Completion date July 12, 2022

See also
  Status Clinical Trial Phase
Completed NCT03894046 - Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex Phase 3
Recruiting NCT05905055 - P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales Phase 3
Completed NCT02420366 - Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Completed NCT01292031 - Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB) Phase 3
Completed NCT02168946 - Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Phase 3
Completed NCT04107363 - Oropharyngeal Aspiration to Reduce Ventilator-Related Pneumonia N/A
Not yet recruiting NCT06087536 - A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex Phase 2
Not yet recruiting NCT01865266 - The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia Phase 2/Phase 3
Withdrawn NCT03006679 - A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Phase 3